Bain Capital Life Sciences

Lincoln Financial Group is a Fortune 500 insurance and financial services company based in Radnor, Pennsylvania, established in 1905 with the endorsement of Robert Todd Lincoln, the son of Abraham Lincoln. The company is dedicated to providing a wide range of products, including life insurance, annuities, retirement plan services, and group protection. It focuses on wealth protection, accumulation, and retirement income solutions, aiming to help individuals secure better futures for themselves and their families. With over a century of experience, Lincoln Financial Group has built its reputation on the principles and ideals associated with Abraham Lincoln, emphasizing honesty and dependability in its financial services.

HealthEdge provides modern, disruptive technology that delivers for the first time, a suite of products that enables healthcare payors to leverage new business models, improve outcomes, drastically reduce administrative costs, and connect everyone in the healthcare delivery cycle. Their next-generation enterprise product suite, HealthRules, is built on modern, patented technology and is delivered to customers via the HealthEdge Cloud or on-site deployment. They enable their customers to radically innovate, drastically reduce costs, and efficiently address the business imperatives of the evolving healthcare economy. HealthEdge was founded by Albert Waxman of Psilos Group and Rob Gillette in December 2004. In January 2005, the company acquired over $125 million in intellectual property and other assets. This technology served as the foundation for the patented, award-winning HealthRules product suite. In December 2012, HealthEdge acquired Click4Care, a care management, and utilization management software company, adding next-generation clinical capabilities to the award-winning HealthRules product suite. HealthEdge is headquartered in Burlington, Massachusetts, and maintains an R&D center in Powell, Ohio.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a severe genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients’ muscles. DMD is a progressive and ultimately fatal condition, with an estimated prevalence of 10,000 to 15,000 cases in the United States. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which targets the LTBP4 protein to reduce fibrosis and inflammation. The company also develops biomarkers, sensors, and the Solid Suit program, which includes wearable assistive devices designed to provide functional and therapeutic benefits. Established in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences collaborates with Ultragenyx to enhance its gene therapy initiatives for DMD.

Abcuro, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of autoimmunity and cancer. Based in Newton, Massachusetts, Abcuro creates therapeutic antibodies targeting novel mechanisms related to these diseases. The company utilizes advanced bioinformatics to analyze transcription data from human diseases, which aids in the identification of new therapeutic targets. Through ex-vivo validation in diseased tissues, Abcuro seeks to uncover innovative methods to modulate key components of the immune system. Established in 2015, Abcuro aims to enhance treatment strategies in the healthcare industry by offering effective solutions for complex immunological conditions.

CereVasc, Inc. is a medical device company dedicated to developing innovative, minimally invasive treatments for neurological diseases. Founded in 2014 and based in Auburndale, Massachusetts, the company focuses on its flagship product, the eShunt System. This system provides an endovascularly deliverable cerebrospinal fluid shunt along with necessary delivery components, designed to eliminate the need for invasive surgical procedures, general anesthesia, and prolonged hospitalization associated with traditional treatments for communicating hydrocephalus. By offering a less invasive option, the eShunt System aims to enhance patient outcomes and reduce the overall costs of surgical interventions for this serious condition.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease. The company was spun out of Pennsylvania-based Knopp, which published results from its phase 2 clinical trial last year that showed its oral drug candidate could reduce the count of blood eosinophil, which is an indication of improving lung function and is found in several asthma-related treatments.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a severe genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients’ muscles. DMD is a progressive and ultimately fatal condition, with an estimated prevalence of 10,000 to 15,000 cases in the United States. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which targets the LTBP4 protein to reduce fibrosis and inflammation. The company also develops biomarkers, sensors, and the Solid Suit program, which includes wearable assistive devices designed to provide functional and therapeutic benefits. Established in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences collaborates with Ultragenyx to enhance its gene therapy initiatives for DMD.

Nimbus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company utilizes advanced computational technologies to create selective and potent small-molecule therapeutics. Among its notable projects is the Nimbus Apollo program, which features the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase (ACC). This compound is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and has potential applications in hepatocellular carcinoma (HCC) and other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, highlighting its significance in the clinical development pipeline. Nimbus Therapeutics has formed strategic partnerships to enhance its research and development capabilities, reinforcing its commitment to advancing treatment options for complex health challenges.

Alkeus Pharmaceuticals is a Boston-based clinical-stage biopharmaceutical company dedicated to developing treatments for serious and untreatable ophthalmic conditions. The company's primary focus is on its lead drug candidate, an orally delivered compound aimed at addressing Stargardt disease and age-related macular degeneration. This innovative treatment has the potential to help medical professionals manage symptoms of irreversible vision loss early in life, offering hope to patients affected by these debilitating eye diseases.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, founded in 2017. The company focuses on developing human genetics-based therapeutics aimed at addressing ineffective red blood cell production in hematologic diseases. Its innovative pipeline includes therapies such as bitopertin for treating erythropoietic porphyrias and Diamond-Blackfan anemia. Disc Medicine targets the hepcidin metabolism axis and aims to modify fundamental biological pathways related to red blood cell formation and function, including heme biosynthesis and iron homeostasis. Through its portfolio of clinical and preclinical product candidates, the company strives to transform the lives of patients suffering from severe hematologic disorders.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, that focuses on drug discovery through its innovative platform targeting solute carrier (SLC) transporters. Established in 2016, the company aims to improve patient outcomes by developing small molecule therapies for various diseases, including those related to immunometabolism, lysosomal function, and mucosal defense. By utilizing advanced chemoproteomics techniques, Jnana accelerates the identification of therapeutic targets, addressing significant unmet medical needs in areas such as immuno-oncology, inflammatory disorders, and neurological diseases. The company's approach seeks to enhance drug discovery efficiency by comprehensively targeting the vast family of membrane proteins associated with SLC transporters.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a severe genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients’ muscles. DMD is a progressive and ultimately fatal condition, with an estimated prevalence of 10,000 to 15,000 cases in the United States. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which targets the LTBP4 protein to reduce fibrosis and inflammation. The company also develops biomarkers, sensors, and the Solid Suit program, which includes wearable assistive devices designed to provide functional and therapeutic benefits. Established in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences collaborates with Ultragenyx to enhance its gene therapy initiatives for DMD.

Nimbus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company utilizes advanced computational technologies to create selective and potent small-molecule therapeutics. Among its notable projects is the Nimbus Apollo program, which features the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase (ACC). This compound is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and has potential applications in hepatocellular carcinoma (HCC) and other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, highlighting its significance in the clinical development pipeline. Nimbus Therapeutics has formed strategic partnerships to enhance its research and development capabilities, reinforcing its commitment to advancing treatment options for complex health challenges.

Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease. The company was spun out of Pennsylvania-based Knopp, which published results from its phase 2 clinical trial last year that showed its oral drug candidate could reduce the count of blood eosinophil, which is an indication of improving lung function and is found in several asthma-related treatments.

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for primary immune deficiencies and cancer. The company's lead candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4, currently undergoing multiple clinical trials. It is in Phase III for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, and in Phase Ib for severe congenital neutropenia and Waldenström macroglobulinemia. Additionally, mavorixafor is being explored in Phase IIa trials for clear cell renal cell carcinoma. X4 Pharmaceuticals is also advancing X4P-002, targeting glioblastoma multiforme, and X4P-003 for primary immune deficiencies. The company has partnered with Abbisko Therapeutics Co., Ltd. to develop mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. and rebranded in March 2019.

Hometap is a fintech company founded in 2018 and based in Boston, Massachusetts, that specializes in home equity investments. It offers homeowners a unique opportunity to access cash without incurring debt or selling their property. By providing immediate funds in exchange for a percentage of the home's future value, Hometap enables homeowners to utilize the money for various purposes, such as paying off debt or financing renovations. This approach allows homeowners to improve their financial situation without the burden of monthly payments or additional loans.

OverIT is a prominent provider of Field Service Management (FSM) software solutions, boasting over 20 years of experience in addressing complex field service challenges for enterprise businesses worldwide. The company serves over 300 clients, enhancing efficiency in linear asset management and facilitating the dispatch of more than 200,000 field workers daily. OverIT specializes in sectors such as energy and utilities, oil and gas, industrial manufacturing, and transportation, offering software that supports system upgrades, field service management, and hardware configurations. Recognized by leading advisory firms like IDC and Gartner, OverIT is acknowledged for its cutting-edge technology and ability to deliver scalable solutions that meet the critical operational needs of its clients.

Cardurion Pharmaceuticals, LLC is a biotechnology company based in Boston, Massachusetts, established in 2017. The company specializes in developing innovative therapeutics aimed at treating heart failure and other cardiovascular diseases. Cardurion is advancing clinical programs that focus on inhibiting PDE9 and CaMKII, utilizing its knowledge of cardiovascular signaling pathways to meet significant patient needs in this area.

ConvenientMD LLC is an urgent care provider that offers a wide range of medical services for non-life-threatening injuries and illnesses. Established in 2011 and headquartered in Portsmouth, New Hampshire, the company caters to patients seeking treatment for conditions such as sprains, fractures, cuts, colds, bronchitis, and urinary tract infections. Additionally, ConvenientMD provides preventive care services, including physicals, immunizations, and on-site prescriptions, as well as X-ray and lab services. Patients can access care without appointments from 8 am to 8 pm, seven days a week, with the expectation of being treated within an hour. The organization emphasizes quality care and customer service, employing a fully equipped medical team at its locations across New Hampshire, Maine, and Massachusetts, with plans for further expansion in New England.

Cerevel Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuroscience diseases. Established in 2018 and based in Cambridge, Massachusetts, the company is advancing a diversified pipeline that includes several clinical-stage investigational therapies targeting conditions such as schizophrenia, epilepsy, Parkinson's disease, and substance use disorder. Notable products in development include CVL-231, a positive allosteric modulator currently in Phase Ib trials for schizophrenia, and CVL-865, also a positive allosteric modulator, which is in Phase II trials for drug-resistant focal onset seizures. Additionally, Tavapadon, a selective dopamine D1/D5 partial agonist, is in a Phase III program for Parkinson's disease, while CVL-936, a selective dopamine D3-preferring antagonist, is undergoing Phase I trials for substance use disorder. The company is also engaged in preclinical research aiming to address various neuroscience indications, leveraging expertise in neurocircuitry and receptor selectivity.

Hand In Hand Soap, founded in 2011 by Bill Glaab and Courtney Apple, is a personal care brand based in Wynnewood, Pennsylvania. The company is committed to social responsibility through its Give Back program, which ensures that for every product sold, a bar of soap and access to clean water is donated to a child in need. Over the past decade, Hand In Hand has donated over 13 million bars of soap and provided thousands with clean water access. The brand's product range includes bar soap, liquid hand soap, hand sanitizer, body wash, sugar scrubs, and lotions. Additionally, Hand In Hand emphasizes sustainability by producing only palm oil-free products and raising awareness about the environmental and human rights issues associated with palm oil production.

Harry's, Inc. is a New York-based company that specializes in manufacturing and selling shaving products tailored for men. Founded in 2012, Harry's offers a comprehensive range of products, including razors, shaving creams, grooming kits, and face care items. The company operates an online platform that allows consumers to purchase these products a-la-carte or through a subscription model, ensuring convenience for customers seeking to fulfill their grooming needs. By designing and producing its own line of razors and replacement blades, Harry's emphasizes quality and accessibility in the men's grooming market.

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for primary immune deficiencies and cancer. The company's lead candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4, currently undergoing multiple clinical trials. It is in Phase III for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, and in Phase Ib for severe congenital neutropenia and Waldenström macroglobulinemia. Additionally, mavorixafor is being explored in Phase IIa trials for clear cell renal cell carcinoma. X4 Pharmaceuticals is also advancing X4P-002, targeting glioblastoma multiforme, and X4P-003 for primary immune deficiencies. The company has partnered with Abbisko Therapeutics Co., Ltd. to develop mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. and rebranded in March 2019.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

River 3 Renal is a developer of novel therapies designed to target orphan diseases in the renal space. The company's technology has the potential to address the unmet need in several kidney diseases, by further improving the standard of care, enabling medical practitioners to treat patients in a better way. River 3 Renal was established in 2020 in New York, USA.

TeachTown Inc. specializes in developing educational solutions for children diagnosed with autism spectrum disorder, developmental disabilities, intellectual disabilities, and emotional and behavioral disorders. The company's flagship products include TeachTown Basics, a computer-assisted instructional program that combines engaging computer lessons with motivating off-computer activities, and TeachTown Social Skills, an online curriculum that utilizes character-based video modeling to enhance social skills in elementary and middle school children. Additionally, TeachTown provides professional development resources for educators, enabling them to effectively implement its programs in the classroom. With a focus on improving academic, social, and emotional skills, TeachTown serves schools, families, and clinicians, facilitating the educational growth of children with special needs. Founded in 2001 and based in Woburn, Massachusetts, the company has positioned itself as a key resource in the field of special education.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on transforming the drug discovery and delivery process to address the rising costs of medicines. Founded in 2019, EQRx aims to provide a market-based solution by leveraging advances in science and technology while collaborating with various healthcare stakeholders. The company has over ten programs in its pipeline targeting oncology and immune-inflammatory conditions, which include clinical and preclinical stages, as well as drug engineering initiatives. Among its key programs are Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab. Through its innovative approach, EQRx seeks to develop high-quality, patent-protected medicines more efficiently and cost-effectively than traditional pharmaceutical methods.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a severe genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients’ muscles. DMD is a progressive and ultimately fatal condition, with an estimated prevalence of 10,000 to 15,000 cases in the United States. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which targets the LTBP4 protein to reduce fibrosis and inflammation. The company also develops biomarkers, sensors, and the Solid Suit program, which includes wearable assistive devices designed to provide functional and therapeutic benefits. Established in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences collaborates with Ultragenyx to enhance its gene therapy initiatives for DMD.

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, that focuses on discovering and developing antiviral therapies for severe viral infections. The company's lead candidate, AT-527, is an antiviral agent currently undergoing phase 3 clinical trials for the treatment of COVID-19, caused by SARS-CoV-2. Additionally, Atea is developing several other product candidates, including AT-787, which is in phase 2 trials for hepatitis C, and AT-752 for dengue. Other candidates, such as AT-889 and AT-934, are also in phase 2 clinical trials targeting respiratory syncytial virus. Established in 2014, Atea Pharmaceuticals aims to improve treatment options for patients suffering from serious viral infections.

Broadstep Behavioral Health provides a continuum of physical, emotional, and mental support for children and adults with intellectual and development disabilities (I/DD), mental illness, and co-occurring disorders. Broadstep has grown to now serve more than 1,300 individuals in 86 facilities across Wisconsin, North Carolina, New Jersey, Illinois and South Carolina. With outcomes rooted in discovering and championing personal definitions of progress, our individuals, families, caregivers, and neighbors are building more and more communities people can call home.

Rapid Micro Biosystems is a life sciences technology company that specializes in products designed to detect microbial contamination in the manufacturing processes of pharmaceutical, biotechnology, and personal care products. Its flagship offering, the Growth Direct System, automates and modernizes traditional microbial quality control testing, providing a non-destructive method for microbial enumeration. The company, originally established as Genomic Profiling Systems in 2006, rebranded in 2007 and is headquartered in Lowell, Massachusetts, with an additional office in Germany. In addition to its automated systems, Rapid Micro Biosystems offers a range of services, including on-site installation, regulatory compliance assistance, system certification training, and technical support, serving clients across the Americas and Europe. Their solutions are utilized in various applications such as environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and release of critical healthcare products.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing innovative vaccines using its proprietary Multiple Antigen Presenting System (MAPS) technology. This approach allows for the combination of protective polysaccharides and proteins into a single vaccine, thereby enhancing immune responses against a variety of infectious diseases affecting both children and adults. Affinivax targets several significant pathogens, including Streptococcus pneumoniae, bacterial nosocomial infections, Salmonella typhi, and Staphylococcus aureus. The company aims to create vaccines that not only provide broader disease coverage compared to existing options but also address infectious diseases lacking effective immunization strategies. Founded in 2014, Affinivax benefits from the expertise of leading professionals in infectious diseases and vaccines, and it has received backing from the Bill & Melinda Gates Foundation, along with an exclusive license from Boston Children’s Hospital for its MAPS technology.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, that specializes in the discovery and development of novel small molecule therapeutics aimed at selectively degrading disease-causing proteins. The company utilizes a proprietary platform for targeted protein degradation, leveraging the body’s natural protein recycling system. Kymera is developing several programs, including the IRAK4 program for immunology-inflammation diseases such as hidradenitis suppurativa and rheumatoid arthritis, the IRAKIMiD program to address MYD88-mutated diffuse large B cell lymphoma, and the STAT3 program targeting hematologic malignancies, solid tumors, and autoimmune diseases. Founded in 2015, Kymera Therapeutics is pioneering new approaches to treat diseases that have previously been considered untreatable, focusing on previously inaccessible therapeutic targets.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on transforming the drug discovery and delivery process to address the rising costs of medicines. Founded in 2019, EQRx aims to provide a market-based solution by leveraging advances in science and technology while collaborating with various healthcare stakeholders. The company has over ten programs in its pipeline targeting oncology and immune-inflammatory conditions, which include clinical and preclinical stages, as well as drug engineering initiatives. Among its key programs are Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab. Through its innovative approach, EQRx seeks to develop high-quality, patent-protected medicines more efficiently and cost-effectively than traditional pharmaceutical methods.

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for rare seizure disorders and neuropsychiatric conditions. The company's primary product candidate, ganaxolone, is an allosteric modulator of GABAA receptors, designed for both intravenous and oral administration for various patient populations. It aims to address multiple indications, including status epilepticus, cyclin dependent kinase-like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, postpartum depression, and treatment-resistant depression. Marinus Pharmaceuticals collaborates with NovaMedica and has license agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals to advance its research and therapeutic offerings. Founded in 2003, the company is headquartered in Radnor, Pennsylvania.

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for cancers linked to abnormal gene expression and drug resistance. The company specializes in the field of epigenetics, targeting selective regulators of epigenetic function that are vital for gene expression control. Its lead product candidates include CPI-0610, currently in Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is undergoing Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is advancing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial aimed at treating solid tumors. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Epigenetix, Inc. before rebranding in March 2008.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a severe genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients’ muscles. DMD is a progressive and ultimately fatal condition, with an estimated prevalence of 10,000 to 15,000 cases in the United States. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which targets the LTBP4 protein to reduce fibrosis and inflammation. The company also develops biomarkers, sensors, and the Solid Suit program, which includes wearable assistive devices designed to provide functional and therapeutic benefits. Established in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences collaborates with Ultragenyx to enhance its gene therapy initiatives for DMD.

Robot Ventures is a venture capital firm founded in 2019 and based in New York, specializing in early-stage investments in the fintech and blockchain sectors. The firm focuses on (pre-)seed funding for innovative companies led by ambitious founders who possess unique and contrarian perspectives. Robot Ventures typically invests between $25,000 and $100,000 per company, targeting sectors such as software, cryptocurrency, and financial services. Through its investments, the firm aims to support exceptional entrepreneurs and drive growth within the rapidly evolving financial technology landscape.

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing medicines for underserved patient populations affected by rare diseases and cancer. The company employs a precision medicine approach and has a diverse portfolio of small molecule targeted oncology products. Its lead candidate, nirogacestat, an oral gamma secretase inhibitor, is currently in Phase III clinical trials for desmoid tumors. Additionally, SpringWorks is advancing several other product candidates, including mirdametinib, an oral MEK inhibitor in Phase IIb trials for neurofibromatosis type 1-associated plexiform neurofibromas, and various combinations involving nirogacestat for multiple myeloma. The company has established collaborations with organizations such as BeiGene, GlaxoSmithKline, and Allogene, aimed at enhancing the development of its therapies. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks is committed to unlocking the potential of its pipeline to provide innovative solutions for patients suffering from cancer and rare diseases.

Cerevel Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuroscience diseases. Established in 2018 and based in Cambridge, Massachusetts, the company is advancing a diversified pipeline that includes several clinical-stage investigational therapies targeting conditions such as schizophrenia, epilepsy, Parkinson's disease, and substance use disorder. Notable products in development include CVL-231, a positive allosteric modulator currently in Phase Ib trials for schizophrenia, and CVL-865, also a positive allosteric modulator, which is in Phase II trials for drug-resistant focal onset seizures. Additionally, Tavapadon, a selective dopamine D1/D5 partial agonist, is in a Phase III program for Parkinson's disease, while CVL-936, a selective dopamine D3-preferring antagonist, is undergoing Phase I trials for substance use disorder. The company is also engaged in preclinical research aiming to address various neuroscience indications, leveraging expertise in neurocircuitry and receptor selectivity.

Rocket Software, Inc. is a provider of enterprise software solutions that focuses on IT modernization and automation services. Established in 1990 and headquartered in Waltham, Massachusetts, the company offers a wide range of products including application lifecycle management, business intelligence, data migration, enterprise performance management, and mainframe modernization. It serves numerous industries, such as automotive, healthcare, finance, and technology, providing tools and services that help businesses optimize their infrastructure, data, and applications. Additionally, Rocket Software offers training, technical support, and professional services to help clients navigate complex IT challenges and enhance their operational capabilities. With a global presence across North America, Europe, and the Asia-Pacific region, Rocket Software is committed to delivering innovative solutions tailored to meet the evolving needs of its diverse customer base.

Rapid Micro Biosystems is a life sciences technology company that specializes in products designed to detect microbial contamination in the manufacturing processes of pharmaceutical, biotechnology, and personal care products. Its flagship offering, the Growth Direct System, automates and modernizes traditional microbial quality control testing, providing a non-destructive method for microbial enumeration. The company, originally established as Genomic Profiling Systems in 2006, rebranded in 2007 and is headquartered in Lowell, Massachusetts, with an additional office in Germany. In addition to its automated systems, Rapid Micro Biosystems offers a range of services, including on-site installation, regulatory compliance assistance, system certification training, and technical support, serving clients across the Americas and Europe. Their solutions are utilized in various applications such as environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and release of critical healthcare products.

Penn Foster College, Penn Foster Career School, and Penn Foster High School are part of Penn Foster, Inc., a global leader in online education. For more than 118 years, Penn Foster has been providing accredited career-focused degree and vocational programs in the fields of allied health, business, technology, education, and select trades. Nationally and regionally accredited Penn Foster High School (www.PennFosterHighSchool.com) and Penn Foster Career School (www.pennfoster.edu) are headquartered in Scranton, PA, with regional offices in Montreal, Canada. Penn Foster College is headquartered in Scottsdale, Arizona.

World Wide Packaging LLC is a designer and manufacturer of packaging products tailored for the cosmetic, skincare, and personal care markets. Established in 1980 and headquartered in Florham Park, New Jersey, the company operates an additional facility in Woodland Hills, California. Its extensive product offerings include a variety of packaging solutions such as blush and foundation sticks, cosmetic bottles, metal and plastic lipstick cases, compacts, jars, and tubes for lip gloss, eyeliner, and mascara. Furthermore, World Wide Packaging provides contract manufacturing services that encompass market research, product development, formulation, filling, and secondary packaging solutions. The company is known for its custom-engineered solutions and offers a range of products from basic plastic containers to sophisticated metal packaging, ensuring high quality and competitive pricing for its clients.

Justworks, Inc. offers a cloud-based platform that simplifies payroll, benefits, human resources, and compliance for small and medium-sized businesses. Founded in 2012 and headquartered in New York, the company provides a comprehensive solution that allows businesses to efficiently manage employment-related responsibilities. Its services include access to affordable health insurance and employee benefits, streamlined payroll processing, and tools for compliance and documentation management. Justworks also offers 24/7 human support and on-demand expertise to assist entrepreneurs in navigating workforce management challenges. By leveraging a professional employer organization model, Justworks enables businesses to achieve cost savings and enhance their employee benefits offerings.

Basis, founded in 2017 and located in Hoboken, New Jersey, is a company that develops an algorithmic cryptocurrency protocol. This protocol operates similarly to a central bank, designed to regulate the supply of cryptocurrency in a dynamic manner. By expanding and contracting supply, Basis aims to stabilize purchasing power, akin to how traditional central banks manage fiscal debt. The cryptocurrency associated with Basis incorporates this algorithmic approach, allowing for adjustments in response to market conditions.

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing medicines for underserved patient populations affected by rare diseases and cancer. The company employs a precision medicine approach and has a diverse portfolio of small molecule targeted oncology products. Its lead candidate, nirogacestat, an oral gamma secretase inhibitor, is currently in Phase III clinical trials for desmoid tumors. Additionally, SpringWorks is advancing several other product candidates, including mirdametinib, an oral MEK inhibitor in Phase IIb trials for neurofibromatosis type 1-associated plexiform neurofibromas, and various combinations involving nirogacestat for multiple myeloma. The company has established collaborations with organizations such as BeiGene, GlaxoSmithKline, and Allogene, aimed at enhancing the development of its therapies. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks is committed to unlocking the potential of its pipeline to provide innovative solutions for patients suffering from cancer and rare diseases.

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for rare seizure disorders and neuropsychiatric conditions. The company's primary product candidate, ganaxolone, is an allosteric modulator of GABAA receptors, designed for both intravenous and oral administration for various patient populations. It aims to address multiple indications, including status epilepticus, cyclin dependent kinase-like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, postpartum depression, and treatment-resistant depression. Marinus Pharmaceuticals collaborates with NovaMedica and has license agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals to advance its research and therapeutic offerings. Founded in 2003, the company is headquartered in Radnor, Pennsylvania.

Replimune Group is a biotechnology company focused on developing oncolytic immune-gene therapies for cancer treatment. Utilizing its proprietary Immulytic platform, Replimune aims to create product candidates that activate the immune system against tumors. The company's lead candidate, RP1, is a modified herpes simplex virus currently undergoing Phase I/II clinical trials for various solid tumors and Phase II trials specifically for cutaneous squamous cell carcinoma. Additionally, Replimune is developing RP2, which targets CTLA-4 to enhance immune response, and RP3, designed to express immune-activating proteins that stimulate T cells. Founded in 2015 and based in Woburn, Massachusetts, Replimune seeks to advance its therapies through clinical trials and explore combinations with other immuno-oncology treatments to enhance efficacy.

Dicerna Pharmaceuticals is a biotechnology company dedicated to the discovery and development of innovative treatments for rare inherited diseases and other conditions affecting the liver. Utilizing its proprietary ribonucleic acid interference (RNAi) technology, specifically the GalXC platform, Dicerna focuses on silencing disease-causing genes to develop pharmaceuticals for various therapeutic areas, including liver diseases, cardiovascular diseases, and cancers. Key product candidates include nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B virus infection, and additional programs targeting undisclosed rare liver diseases. The company has established strategic collaborations with several major pharmaceutical firms to enhance its research and development efforts. Founded in 2006 and headquartered in Lexington, Massachusetts, Dicerna Pharmaceuticals aims to address significant unmet medical needs through its innovative approaches.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a severe genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients’ muscles. DMD is a progressive and ultimately fatal condition, with an estimated prevalence of 10,000 to 15,000 cases in the United States. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which targets the LTBP4 protein to reduce fibrosis and inflammation. The company also develops biomarkers, sensors, and the Solid Suit program, which includes wearable assistive devices designed to provide functional and therapeutic benefits. Established in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences collaborates with Ultragenyx to enhance its gene therapy initiatives for DMD.

Daymon Worldwide, Inc. is a leading provider of consumables retailing services, specializing in branding, sourcing, and the commercialization of customized retail solutions. The company offers a wide range of services, including private brand development, which encompasses brand strategy, program management, product sourcing, and supplier management. Additionally, Daymon provides comprehensive strategy and branding services, such as brand identity design, digital marketing, and category analytics. The company also focuses on sourcing and logistics, optimizing supply chains and managing global distribution. Its retail services include store remodeling, auditing, and online reporting. Furthermore, Daymon engages in consumer experience marketing through in-store sampling, taste tests, and mystery shopping. Serving diverse retailer customers across various sectors, including automotive, convenience stores, and e-commerce, Daymon Worldwide leverages over 40 years of industry experience to deliver tailored strategies that enhance brand presence and drive sales. Founded in 1970 and based in Stamford, Connecticut, the company was previously known as Daymon Associates, Inc. before rebranding in 2003.

Sundial Brands, LLC is a manufacturer of skin care and hair care products, specializing in a diverse range of offerings that include soaps, deodorants, body washes, lotions, shampoos, and various treatments for both adults and children. Founded in 1992 and based in Amityville, New York, the company is dedicated to using high-quality, natural, certified organic, and ethically-sourced ingredients in its formulations. Sundial Brands distributes its products through various retailers across the United States. It operates as a subsidiary of Unilever United States, Inc.

Founded in 1996, Blue Coat is now an industry leader in the field of advanced enterprise security. Originally founded as CacheFlow, the company changed its name to Blue Coat in 2002 to reflect its new emphasis on enterprise security, invoking the image of a baseball umpire’s uniform. In March 2015, Blue Coat was acquired by private equity firm Bain Capital. Blue Coat provides advanced enterprise security for 15,000 organizations across the globe, numbering 88 of the 100 largest global companies among them. The Blue Coat Security Platform provides an integrated platform that addresses companies’ network, security, and cloud requirements. This allows customers a minimal impact on network performance while still providing top-quality protection against advanced threats and improving performance for cloud applications and services. Blue Coat focuses strongly on growth and innovation, with 200 patents issued and pending. Blue Coat also maintains several Research and Development centers across the globe, with facilities in Sunnyvale, California; Draper, Utah; Waterloo, Ontario; Boxborough, Massachusetts; and Lysaker, Norway. The company also providers 24/7 “Follow the Sun” Model Global Support from each of its six support centers. Particularly in recent years, Blue Coat has achieved significant positive recognition within the industry, receiving many awards. Among these accolades are the Frost & Sullivan 2016 Global Network Security Forensics Market Leadership Award; the Frost & Sullivan 2014 Web Security Vendor of the Year Award; the 2015 Cloud Computing Magazine Cloud Computing Excellence Award; and the 2015 Best Cloud Computing Security Solution, Reader Trust Award from SC Magazine.

Turbonomic is a Boston-based software provider specializing in Application Resource Management (ARM) and Network Performance Management (NPM). The company offers AI-powered technology designed to optimize application performance, compliance, and cost in real time. Its hybrid cloud management platform integrates with leading application performance management and IT service management solutions, creating a unified control plane for automating IT resource management. By dynamically adjusting resource supply based on workload demand, Turbonomic enables organizations to maintain optimal application health across on-premises and multi-cloud environments. This capability allows businesses to self-manage their IT resources in real time, ensuring performance while reducing costs.

SevOne, Inc. develops infrastructure performance monitoring and analytics solutions designed to meet the needs of a variety of sectors, including communications service providers, financial services, and government organizations. The company offers a range of products, including the SevOne Data Platform, which collects and analyzes multi-vendor network performance metrics; SevOne Data Insight, which facilitates customizable visualizations for enhanced network monitoring; and SevOne Data Cloud, providing real-time and historical insights from network streaming telemetry. Additionally, SevOne features solutions for software-defined networking and SD-WAN monitoring, aimed at managed services providers. The company is known for its patented SevOne Cluster architecture, which enables rapid monitoring of devices across complex infrastructures, ensuring swift responses to potential performance issues. SevOne serves a global customer base that includes top investment services firms and large enterprises, helping them navigate the challenges of dynamic network environments. Established in 2003 and headquartered in Boston, Massachusetts, SevOne operates as a subsidiary of Turbonomic, Inc.

BuyWithMe is a group-buying platform that connects local merchants with consumers by offering limited-time deals on various services, including dining, entertainment, and wellness. The app enables users to discover exclusive offers tailored to their location, helping them save money while supporting local businesses. Through a mobile digital asset wallet, BuyWithMe facilitates seamless payments using QR codes and allows transactions in multiple cryptocurrencies, such as Bitcoin and Ethereum, ensuring flexibility for users. The app also features a unique QR code for each customer, enabling easy money transfers between users without the need for traditional point-of-sale systems. Founded in New York City and with an additional office in Austin, BuyWithMe aims to innovate the future of payment and commerce under the leadership of its founders, Andrew Moss and Zsolt Sasdi.

Helomics Corporation is a personalized healthcare company focused on oncology, providing innovative tools to assist physicians and patients in making informed decisions throughout the cancer care continuum. It has developed a Precision Cellular Analytical Platform that analyzes cellular data over a 25-35 day period. Among its key products are ChemoFx, which aids in selecting effective treatments for gynecologic cancer patients; BioSpeciFx, offering biomarker tests for evaluating tumor responses at the molecular level; and GeneFx products, which use gene signatures to inform treatment options for colon and lung cancer patients. Additionally, Helomics provides tumor profiling services, including bioinformatics and patient-derived tumor models, which enhance clinical research and drug development. The company employs artificial intelligence through its D-CHIP platform to create personalized oncology roadmaps for patients. Founded in 1995 and headquartered in Pittsburgh, Pennsylvania, Helomics operates as a subsidiary of Predictive Oncology Inc.

Bright Horizons, founded in 1986 and based in Newton, Massachusetts, is a prominent provider of high-quality education and childcare services. The company specializes in early education and preschools, employer-sponsored childcare, backup care, and educational advisory services. Bright Horizons is dedicated to nurturing each child's unique qualities and potential while fostering strong partnerships with families. The organization collaborates with employers to create family-friendly workplaces and promotes a professional environment that encourages growth and diversity. By focusing on these key areas, Bright Horizons aims to support families effectively and maintain a financially robust organization.

Burlington Stores, Inc. is a prominent off-price retailer in the United States, specializing in branded apparel and home products. Founded in 1972 and headquartered in Burlington, New Jersey, the company offers a diverse range of fashion-focused merchandise, including women's and men's apparel, youth clothing, baby products, accessories, footwear, and home décor. Burlington Stores is known for providing high-quality, current-brand merchandise at significant discounts, often up to 65% off retail prices. As of late 2020, the company operated 769 stores across 45 states and Puerto Rico, catering to a wide customer base with a focus on affordability and variety. The retailer also features a selection of products for babies and home essentials, ensuring a comprehensive shopping experience for families.

Network Intelligence Corporation provides security information and event management solutions. Its products include enVision that collects and protects data, as well as provides security and compliance analysis, and reporting and alerting solutions; Intelligence Engine software/hardware network security appliances for security information and event management market; and LogSmart Internet Protocol Database, which provides architecture to collect and protect the data from various Internet protocol devices. The company's strategic partners include Microsoft; NetworkAppliance; IBM; EMC2; EDS; Check Point Software Technologies, Ltd.; and Juniper Networks. Network Intelligence Corporation was formerly known as OpenSystems.com, Inc. and changed its name to Network Intelligence Corporation. The company was founded in 1996 and is headquartered in Westwood, Massachusetts. It also has offices in Rancho Santa Margarita, California; Chicago, Illinois; Alpharetta, Georgia; Seabrook, Texas; Arlington, Virginia; Amsterdam, the Netherlands; Paris, France; and London.

ProfitLogic specializes in developing and marketing retail profit optimization software solutions. The company provides a comprehensive suite of tools aimed at enhancing profitability across various retail sectors. Its offerings include software for price optimization, inventory planning, assortment and allocation, in-season inventory management, promotions, and performance assessment. These applications assist retailers in making informed decisions regarding allocation, planning, and pricing to maximize their financial outcomes. Founded in 1983 and based in Cambridge, Massachusetts, ProfitLogic was previously known as Technology Strategy, Inc.

deNovis Inc. is a leading provider of advanced transaction processing and information management solutions for the health insurance and health care benefits administration industry. deNovis's highly innovative claims processing and data management software enables commercial and government health plans to reduce administrative costs, expand their range of products and services, increase speed-to-market of new products and enhance the quality of customer service. The company's flagship software product—eHD™—serves as the core administrative platform for health plans and is designed to deliver the sophistication necessary to meet both existing and emerging needs of commercial, Medicare and Medicaid healthcare benefits administrators. deNovis is also known for its technical innovations, including HICL™ technology, which allows complex healthcare transaction systems to be programmed by business analysts rather than computer programmers, using English language commands and the actual policies and business rules of the health plan. deNovis's customer roster includes large commercial insurers and the U. S. Department of Health and Human Services—the nation's largest purchaser of healthcare and a provider of healthcare benefits to almost 80 million Americans. The company's strategic alliance partners include IBM Corporation and Deloitte Consulting. deNovis enterprise solutions for health plans are available for installation at customer locations or can be delivered on an outsourced or remote-hosted basis. The company is privately held and is headquartered in Lexington, Massachusetts.

TravelClick provides cloud-based software solutions for hoteliers worldwide. It offers reservation solutions such as iHotelierm that is a central reservation system, iHotelier Web 3.0 that is a game-changing web booking engine, iHotelier Mobile that is a mobile booking engine, iHotelier Global Distribution Systems (GDS) that promotes hotel’s availability in third party channels, Channel Management that provides hotel channel management solutions, iHotelier VoicePro, a private label voice reservations solution, iHotelier Demand that offers access to distribution channels and partnerships, and iHotelier PMS, a property management system solution. TravelClick provides business intelligence solutions that include Rate360 that is a rate comparison tool, Agency360 that gives access to the database of agency bookings, Demand360 that offers access to information and in-depth reports and Enterprise Solutions that is a platform that provides market research and analytical tools. It offers media solutions such as Travel Agent Media that is a solution that drives high value bookings, Display Marketing that is a tool for researching hotels and display remarketing, and Pay-Per-Click Advertising that helps to drive traffic and bookings to hotel’s website. TravelClick provides web solutions in the areas of custom websites, search engine optimization, and social media optimization, guest management, a customer relationship management database and e-mail marketing solution, and training and support services. Global Marketing Services that began operation in 1987 later became TravelClick. TravelClick has its headquarters in New York City. It has additional offices in Barcelona in Spain, Chicago in Illinois in Dubai in the United Arab Emirates, Atlanta in Georgia, Melbourne in Australia, Singapore, Shanghai in China; Hong Kong, New York City, Philadelphia in Pennsylvania, Orlando in Florida, and Tokyo in Japan.

ProfitLogic specializes in developing and marketing retail profit optimization software solutions. The company provides a comprehensive suite of tools aimed at enhancing profitability across various retail sectors. Its offerings include software for price optimization, inventory planning, assortment and allocation, in-season inventory management, promotions, and performance assessment. These applications assist retailers in making informed decisions regarding allocation, planning, and pricing to maximize their financial outcomes. Founded in 1983 and based in Cambridge, Massachusetts, ProfitLogic was previously known as Technology Strategy, Inc.

deNovis Inc. is a leading provider of advanced transaction processing and information management solutions for the health insurance and health care benefits administration industry. deNovis's highly innovative claims processing and data management software enables commercial and government health plans to reduce administrative costs, expand their range of products and services, increase speed-to-market of new products and enhance the quality of customer service. The company's flagship software product—eHD™—serves as the core administrative platform for health plans and is designed to deliver the sophistication necessary to meet both existing and emerging needs of commercial, Medicare and Medicaid healthcare benefits administrators. deNovis is also known for its technical innovations, including HICL™ technology, which allows complex healthcare transaction systems to be programmed by business analysts rather than computer programmers, using English language commands and the actual policies and business rules of the health plan. deNovis's customer roster includes large commercial insurers and the U. S. Department of Health and Human Services—the nation's largest purchaser of healthcare and a provider of healthcare benefits to almost 80 million Americans. The company's strategic alliance partners include IBM Corporation and Deloitte Consulting. deNovis enterprise solutions for health plans are available for installation at customer locations or can be delivered on an outsourced or remote-hosted basis. The company is privately held and is headquartered in Lexington, Massachusetts.

Solect Energy, located in Hopkinton, Massachusetts, is a prominent player in the commercial-scale solar industry. The company focuses on providing solar energy solutions tailored for businesses, helping them harness renewable energy to reduce costs and enhance sustainability. Solect Energy is known for its expertise in designing, financing, and installing solar energy systems, making it a key partner for organizations looking to transition to solar power.

Cortera, Inc. is a provider of business-to-business analytics and cloud-based risk management solutions, specializing in payment and purchase behavior data for both public and private companies. The company tracks $1.6 trillion in business-to-business purchases across 45 spend categories, delivering insights on 20 million U.S. business locations. Its offerings include Cortera Pulse, which monitors credit risk and key events; Boost, which appends scores and insights about customers and suppliers; and Cortera Decisions, an automated scorecard platform. Additionally, Cortera provides eCredit for credit scoring and collections automation, Cortera Traits for real-time statistical modeling, and Connect, an XML web service for accessing proprietary data. With a focus on helping companies understand their customers and partners, Cortera’s solutions enhance revenue generation, improve sales and marketing effectiveness, and mitigate risk. Founded in 1993 and headquartered in Boca Raton, Florida, the company also has offices in Quincy, Massachusetts, and Bengaluru and Coimbatore, India.

TravelClick provides cloud-based software solutions for hoteliers worldwide. It offers reservation solutions such as iHotelierm that is a central reservation system, iHotelier Web 3.0 that is a game-changing web booking engine, iHotelier Mobile that is a mobile booking engine, iHotelier Global Distribution Systems (GDS) that promotes hotel’s availability in third party channels, Channel Management that provides hotel channel management solutions, iHotelier VoicePro, a private label voice reservations solution, iHotelier Demand that offers access to distribution channels and partnerships, and iHotelier PMS, a property management system solution. TravelClick provides business intelligence solutions that include Rate360 that is a rate comparison tool, Agency360 that gives access to the database of agency bookings, Demand360 that offers access to information and in-depth reports and Enterprise Solutions that is a platform that provides market research and analytical tools. It offers media solutions such as Travel Agent Media that is a solution that drives high value bookings, Display Marketing that is a tool for researching hotels and display remarketing, and Pay-Per-Click Advertising that helps to drive traffic and bookings to hotel’s website. TravelClick provides web solutions in the areas of custom websites, search engine optimization, and social media optimization, guest management, a customer relationship management database and e-mail marketing solution, and training and support services. Global Marketing Services that began operation in 1987 later became TravelClick. TravelClick has its headquarters in New York City. It has additional offices in Barcelona in Spain, Chicago in Illinois in Dubai in the United Arab Emirates, Atlanta in Georgia, Melbourne in Australia, Singapore, Shanghai in China; Hong Kong, New York City, Philadelphia in Pennsylvania, Orlando in Florida, and Tokyo in Japan.